SION

Sionna Therapeutics Inc

3.60

Oct 23 • 3:59 PM ET -0.20 (-5.26%)

3.62

Aftermarket • 7:44 PM ET +0.02 (0.56%)

Healthcare Biotechnology USA Micro NASD

Peers: VRTX INSM SVRA AVLN ARMP ELOX PLRX RARE MIST ZVRA

| Held by: VTI IWM VXF IBB IWO VTWO SCHA VHT SBIO VTWG

Scroll to Statements

Index	RUT
Market Cap	162.76M
Enterprise Value	-40.20M
Income	-97.38M
Sales	0.00M
Book/sh	5.88
Cash/sh	4.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	59
IPO	Feb 07, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.61
P/C	0.77
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.05
Current Ratio	20.05
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-2.29
EPS next Q	-0.64
EPS this Y	-31.87%
EPS next Y	7.52%
EPS next 5Y	-11.40%
EPS past 3/5Y	-22.66% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-26.18%
Sales Y/Y TTM	-
EPS Q/Q	-61.68%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-1.54% -

Insider Own	47.89%
Insider Trans	-17.04%
Inst Own	65.54%
Inst Trans	9.59%
ROA	-30.66%
ROE	-32.34%
ROIC	-35.74%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.28%
SMA50	-36.38%
SMA200	-88.37%
Trades

Shs Outstand	45.16M
Shs Float	23.56M
Short Float	16.12%
Short Ratio	1.69
Short Interest	3.80M
52W High	54.97 -93.45%
52W Low	3.64 -1.14%
Volatility	8.43% 7.05%
ATR (14)	0.51
RSI (14)	24.10
Beta	1.12
Rel Volume	0.41
Avg Volume	2.24M
Volume	918,209

Perf Week	-7.46%
Perf Month	-31.17%
Perf Quarter	-92.07%
Perf Half Y	-90.55%
Perf YTD	-91.25%
Perf Year	-90.91%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.82
Target Price	21.57
Prev Close	3.80
Price	3.60
Change %	-5.26%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-26	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$5
Aug-10-26	Downgrade	Wedbush	Outperform → Neutral	$5
Aug-10-26	Downgrade	Stifel	Buy → Hold	$7
Aug-10-26	Downgrade	Raymond James	Strong Buy → Mkt Perform
Aug-10-26	Downgrade	Guggenheim	Buy → Neutral
Aug-10-26	Downgrade	Citizens	Mkt Outperform → Mkt Perform
Aug-10-26	Downgrade	BTIG Research	Buy → Neutral
May-05-26	Initiated	Wedbush	Outperform	$53
Feb-24-26	Initiated	Citizens	Mkt Outperform	$63
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$24
Nov-19-25	Initiated	BTIG Research	Buy	$50
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform	$22
Sep-03-25	Initiated	Raymond James	Strong Buy	$45
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Show Previous Ratings

Oct-08-26 04:30PM	Sionna Therapeutics to Present Data at the 2026 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-21-26 05:06PM	These beaten-down stocks could bounce back in January, if history is any guide (MarketWatch)
Sep-15-26 01:13PM	FDA clears first generic radioligand drug; Sionna turns to layoffs (BioPharma Dive) -16.71%
Sep-14-26 04:01PM	Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial (GlobeNewswire) +5.22%
Aug-19-26 10:22PM	Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics (PR Newswire) +5.22% -11.68%
04:20PM	Loading…
Aug-17-26 04:20PM	Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information (Business Wire) -8.51%
Aug-11-26 09:11AM	Sionna Therapeutics stock falls 92% after SION-719 trial failure (Quartz) +13.33%
Aug-10-26 04:36PM	Immunic appoints Elena Ridloff to board of directors (Proactive) -91.18%
03:14PM	Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low (Barrons.com)
01:18PM	SION Stock On Track For Worst Day Ever After 90% Drop Whats Driving The Selloff? (Stocktwits)
11:55AM	Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails (GuruFocus.com)
10:52AM	Tenax, Sionna Shares Sink After Trial Failures (The Wall Street Journal)
08:48AM	Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint (InvestorsHub)
08:25AM	Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout (Investing.com)
07:00AM	Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update (GlobeNewswire)
07:00AM	Loading…
Aug-06-26 07:00AM	Sionna Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
May-27-26 08:00AM	Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences (GlobeNewswire)
May-13-26 08:00AM	Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.32%
May-12-26 07:00AM	Sionna Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.90%
Apr-27-26 07:00AM	Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire)
Apr-07-26 07:00AM	Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire)
Mar-02-26 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -7.17%
Feb-23-26 08:00AM	Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences (GlobeNewswire)
Feb-15-26 04:41AM	Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit (MarketBeat)
Feb-04-26 07:00AM	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.12%
Jan-05-26 07:00AM	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Nov-24-25 07:00AM	Sionna Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) +7.92%
Nov-05-25 07:00AM	Sionna Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
08:00AM	Loading…
Nov-04-25 08:00AM	Sionna Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) -5.63%
Oct-24-25 01:15PM	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-21-25 07:00AM	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire) +31.99%
Oct-01-25 04:05PM	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-15-25 12:00PM	All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? (Zacks) +13.32%
Sep-08-25 08:00AM	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (GlobeNewswire) -9.92%
Aug-27-25 07:00AM	Sionna Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-25-25 07:00AM	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis (GlobeNewswire)
Aug-11-25 07:00AM	Sionna Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire) +13.36%
Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RA CAPITAL MANAGEMENT, L.P.	Director	Sep 17 '26	Sale	6.33	3,448,811	21,835,018	3,448,812	Sep 21 06:56 PM
RA Capital Healthcare Fund, L.	Director	Sep 17 '26	Proposed Sale	6.33	3,448,811	21,834,318		Sep 17 05:10 PM
Thompson Peter A.	Director	Jul 07 '26	Sale	44.86	85,918	3,854,281	2,469,959	Jul 09 04:47 PM
ORBIMED ADVISORS LLC	Director	Jul 07 '26	Sale	44.86	85,918	3,854,281	2,469,959	Jul 09 04:44 PM
Fitzpatrick Jennifer	Chief Legal Officer	Jul 06 '26	Option Exercise	6.11	10,250	62,628	10,250	Jul 07 04:38 PM
Fitzpatrick Jennifer	Chief Legal Officer	Jul 06 '26	Sale	43.60	10,250	446,862	0	Jul 07 04:38 PM
JENNIFER FITZPATRICK	Officer	Jul 06 '26	Proposed Sale	43.99	10,250	450,898		Jul 06 04:39 PM
Thompson Peter A.	Director	Jun 30 '26	Sale	45.50	115,844	5,270,902	2,555,877	Jul 02 04:45 PM
ORBIMED ADVISORS LLC	Director	Jun 30 '26	Sale	45.50	115,844	5,270,902	2,555,877	Jul 02 04:42 PM
Thompson Peter A.	Director	May 27 '26	Sale	44.49	101	4,493	2,671,721	May 29 09:02 PM
ORBIMED ADVISORS LLC	Director	May 27 '26	Sale	44.49	101	4,493	2,671,721	May 29 08:57 PM
OrbiMed Private Investments VI	Shareholder	May 29 '26	Proposed Sale	42.80	1,082,480	46,330,144		May 29 06:44 PM
Thompson Peter A.	Director	May 11 '26	Sale	46.22	184,639	8,534,015	2,671,822	May 11 07:14 PM
Thompson Peter A.	Director	May 08 '26	Sale	44.58	59,767	2,664,413	2,856,461	May 11 07:14 PM
Thompson Peter A.	Director	May 07 '26	Sale	44.61	48,546	2,165,637	2,916,228	May 11 07:14 PM
ORBIMED ADVISORS LLC	Director	May 11 '26	Sale	46.22	184,639	8,534,015	2,671,822	May 11 06:58 PM
ORBIMED ADVISORS LLC	Director	May 08 '26	Sale	44.58	59,767	2,664,413	2,856,461	May 11 06:58 PM
ORBIMED ADVISORS LLC	Director	May 07 '26	Sale	44.61	48,546	2,165,637	2,916,228	May 11 06:58 PM
Thompson Peter A.	Director	Apr 17 '26	Sale	44.68	52,397	2,341,098	2,967,722	Apr 21 08:42 PM
Thompson Peter A.	Director	Apr 18 '26	Sale	44.52	2,948	131,245	2,964,774	Apr 21 08:42 PM
ORBIMED ADVISORS LLC	Director	Apr 17 '26	Sale	44.68	52,397	2,341,098	2,967,722	Apr 21 08:40 PM
ORBIMED ADVISORS LLC	Director	Apr 18 '26	Sale	44.52	2,948	131,245	2,964,774	Apr 21 08:40 PM
Thompson Peter A.	Director	Apr 15 '26	Sale	44.64	235,863	10,528,924	3,247,025	Apr 16 07:15 PM
Thompson Peter A.	Director	Apr 16 '26	Sale	45.34	226,906	10,287,918	3,020,119	Apr 16 07:15 PM
Thompson Peter A.	Director	Apr 14 '26	Sale	44.51	47,814	2,128,201	3,482,888	Apr 16 07:15 PM
ORBIMED ADVISORS LLC	Director	Apr 15 '26	Sale	44.64	235,863	10,528,924	3,247,025	Apr 16 07:03 PM
ORBIMED ADVISORS LLC	Director	Apr 16 '26	Sale	45.34	226,906	10,287,918	3,020,119	Apr 16 07:03 PM
ORBIMED ADVISORS LLC	Director	Apr 14 '26	Sale	44.51	47,814	2,128,201	3,482,888	Apr 16 07:03 PM
Fitzpatrick Jennifer	Chief Legal Officer	Mar 05 '26	Option Exercise	6.11	10,250	62,628	10,250	Mar 06 06:56 PM
Fitzpatrick Jennifer	Chief Legal Officer	Mar 05 '26	Sale	33.86	10,250	347,019	0	Mar 06 06:56 PM
JENNIFER FITZPATRICK	Officer	Mar 05 '26	Proposed Sale	34.57	10,250	354,342		Mar 05 04:28 PM
Thompson Peter A.	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:43 PM
Thompson Peter A.	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:43 PM
ORBIMED ADVISORS LLC	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:39 PM
ORBIMED ADVISORS LLC	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:39 PM
TPG GP A, LLC	10% Owner	Jan 22 '26	Sale	40.00	250,000	10,000,000	6,494,962	Jan 26 05:24 PM
Rise Fund Sling, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	195,667	8,173,011		Jan 22 08:47 PM
Rise Fund Sling II, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	54,333	2,269,489		Jan 22 08:47 PM
ORBIMED ADVISORS LLC	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:44 PM
Thompson Peter A.	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:42 PM
ORBIMED ADVISORS LLC	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:29 PM
Thompson Peter A.	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:24 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Option Exercise	6.11	10,250	62,628	10,250	Dec 09 04:57 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Sale	40.52	10,250	415,330	0	Dec 09 04:57 PM
JENNIFER R FITZPATRICK	Officer	Dec 05 '25	Proposed Sale	40.88	10,250	419,020		Dec 05 04:27 PM
ORBIMED ADVISORS LLC	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:45 PM
Thompson Peter A.	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:41 PM
OrbiMed Private Investments VI	Shareholder	Nov 24 '25	Proposed Sale	44.38	1,047,770	46,500,033		Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 21 '25	Sale	39.50	25,183	994,728	159,033	Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 20 '25	Sale	40.13	5,133	205,975	166,642	Nov 24 05:43 PM
RA Capital Healthcare Fund LP	Director	Nov 21 '25	Proposed Sale	43.66	1,210	52,829		Nov 21 04:24 PM
RA Capital Nexus Fund III, L.P	Director	Nov 21 '25	Proposed Sale	43.66	6,440	281,170		Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.	Director	Nov 21 '25	Proposed Sale	43.66	9,924	433,282		Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 21 '25	Proposed Sale	43.66	7,609	332,209		Nov 21 04:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 20 '25	Proposed Sale	38.94	1,313	51,128		Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.	Director	Nov 20 '25	Proposed Sale	38.94	2,023	78,776		Nov 20 04:35 PM
RA Capital Healthcare Fund LP	Director	Nov 20 '25	Proposed Sale	38.94	246	9,579		Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 20 '25	Proposed Sale	38.94	1,551	60,396		Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 17 '25	Sale	40.59	81,987	3,328,081	184,619	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 19 '25	Sale	40.01	47,442	1,898,173	168,193	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 18 '25	Sale	39.57	6,922	273,904	182,527	Nov 19 08:43 PM
RA Capital Healthcare Fund LP	Director	Nov 19 '25	Proposed Sale	39.12	2,278	89,115		Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 19 '25	Proposed Sale	38.41	14,334	550,568		Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.	Director	Nov 19 '25	Proposed Sale	38.41	18,696	718,113		Nov 19 05:10 PM
RA Capital Nexus Fund III, L.P	Director	Nov 19 '25	Proposed Sale	38.41	12,134	466,066		Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 18 '25	Proposed Sale	39.04	2,092	81,671		Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.	Director	Nov 18 '25	Proposed Sale	39.04	2,728	106,501		Nov 18 05:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 18 '25	Proposed Sale	39.04	1,770	69,100		Nov 18 05:09 PM
RA Capital Healthcare Fund LP	Director	Nov 18 '25	Proposed Sale	39.04	332	12,961		Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 17 '25	Proposed Sale	39.93	24,772	989,146		Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.	Director	Nov 17 '25	Proposed Sale	39.93	32,310	1,290,138		Nov 17 05:04 PM
RA Capital Nexus Fund III, L.P	Director	Nov 17 '25	Proposed Sale	39.93	20,969	837,292		Nov 17 04:56 PM
RA Capital Healthcare Fund LP	Director	Nov 17 '25	Proposed Sale	39.93	3,936	157,164		Nov 17 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	39.58	62,610	2,478,104	209,391	Oct 28 09:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 28 '25	Proposed Sale	39.45	17,118	675,305		Oct 28 05:13 PM
RA Capital Healthcare Fund LP	Director	Oct 28 '25	Proposed Sale	39.45	3,624	142,967		Oct 28 05:07 PM
RA Capital Nexus Fund, L.P.	Director	Oct 28 '25	Proposed Sale	39.45	31,392	1,238,414		Oct 28 05:05 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 28 '25	Proposed Sale	39.45	10,476	413,278		Oct 28 04:57 PM

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

PresidentMr. Michael Cloonan M.B.A.

CFO & Chief Business OfficerMs. Elena H. Ridloff C.F.A.

Co-Founder & Senior VP of Discovery ResearchDr. Greg Hurlbut Ph.D.

Co-founderDr. Mark Munson Ph.D.

Vice President of Information & TechnologyMr. Andy Chu

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SION

Sionna Therapeutics Inc

Upgrade your Finviz experience